Onkológia 3/2015

Classical and new prognostic factors and their impact on therapeutic procedures in DLBCL

Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occuring lymphoma, accounting for an estimated 35 % of all nonHodgkin´s lymphoma cases worldwide. It has an aggressive natural history, with a median survival of less than one year if left untreated. Despite remarkable progress in improving patient survival, clinical outcomes are still unsatisfactory for certain subsets of patients, including the elderly and very elderly and those with highly aggressive disease. New combinations of antibodies with improved biological activity or new drugs that act in concern with R-CHOP-like regimens may help to target highly malignant tumour cells that are characteristic of high-risk disease. Identification of new prognostic factors in combination with classical as the International Prognostic index (IPI) in the future to think about the treatment of DLBCL designed for individuals.

Keywords: diffuse large B-cell lymphoma, prognostic factors.